#1 Clinical Trials Search in Europe

Etrinabdione

A groundbreaking clinical trial is underway to assess the potential of Etrinabdione, a novel medication, in treating Peripheral Arterial Disease (PAD). This study aims to evaluate the safety, tolerability, and preliminary effectiveness of Etrinabdione in patients with PAD, particularly those experiencing moderate to severe claudication. The trial focuses on patients aged 50 to 85 with type 2 diabetes and explores various aspects of the drug’s impact on vascular health and quality of life.

Table of Contents

What is Etrinabdione?

Etrinabdione is a new medication being tested for the treatment of Peripheral Arterial Disease (PAD). It’s also known by other names such as EHP-101 and VCE-004.8[1]. This drug is a fully synthetic, new chemical entity, which means it’s a completely new medication that has been created in a laboratory[1].

The medication comes in the form of an oral solution, which means it’s a liquid that you drink[1]. Researchers are testing two different doses of Etrinabdione: 25 mg and 50 mg, both taken twice a day[1].

What is Peripheral Arterial Disease?

Peripheral Arterial Disease (PAD) is a condition where the arteries that supply blood to your limbs (usually the legs) become narrowed or blocked. This can cause pain, especially when walking (a symptom called claudication), and can lead to serious complications if left untreated[1].

How Etrinabdione is Being Studied

Researchers are conducting a Phase IIa clinical trial to study Etrinabdione[1]. This type of study is designed to:

  • Test the safety of the medication
  • See how well patients tolerate it
  • Get an early idea of how effective it might be
The study will last for up to 12 months, allowing researchers to observe the long-term effects of the medication[1].

Who Can Participate in the Study?

The study is looking for participants who meet certain criteria. Some key points include:

  • Adults aged 50 to 85 years old
  • Diagnosed with moderate to severe claudication (pain when walking due to PAD)
  • Have Type 2 diabetes with controlled blood sugar levels
  • Do not have certain other health conditions that might interfere with the study
There are also specific rules about who cannot participate, such as people with certain liver problems, HIV, or a history of some types of cancer[1].

What the Study Will Measure

The researchers will be looking at several things during the study[1]:

  • Safety and side effects: They’ll keep track of any adverse events that occur during the study.
  • Vascularization: This means looking at the blood vessels using special imaging techniques.
  • Hemodynamics: They’ll measure blood flow using a test called the ankle/brachial index.
  • Stenosis: This involves checking for narrowing of the blood vessels using ultrasound.
  • Quality of life: Participants will fill out questionnaires about how PAD affects their daily life.
  • Tissue oxygenation: They’ll measure how much oxygen is getting to the tissues in the legs.
  • How the body processes the drug: This involves measuring the levels of the drug in the blood at different times.
  • Biomarkers: These are substances in the blood that can indicate how the disease is progressing or how the body is responding to the treatment.
  • Clinical improvement: They’ll measure how long participants can walk before experiencing pain.

Potential Benefits and Risks

As with any new medication, there are potential benefits and risks to participating in this study:

  • Potential benefits: If Etrinabdione proves effective, it could help improve blood flow in the legs, reduce pain when walking, and improve overall quality of life for people with PAD.
  • Potential risks: As this is a new medication, not all side effects are known. The study is designed to carefully monitor for any adverse effects. Some people may not be able to take the medication if they have certain health conditions or are taking certain other medications[1].

It’s important to note that this is an early-stage study, and more research will be needed to fully understand how well Etrinabdione works and what its side effects might be. If you’re interested in participating in this or any clinical trial, it’s crucial to discuss it with your healthcare provider to understand if it’s right for you[1].

Aspect Details
Drug Name Etrinabdione
Condition Studied Peripheral Arterial Disease (PAD)
Study Type Phase IIa Open Label, Dose-Finding Clinical Trial
Primary Objective Evaluate safety and tolerability of Etrinabdione in PAD patients
Secondary Objectives Assess effects on vascularization, clinical improvement, quality of life, tissue oxygenation, hemodynamics, and stenosis
Participant Age Range 50 to 85 years
Key Inclusion Criteria PAD (Rutherford Category 2 or 3), Type 2 Diabetes, HbA1c < 9%
Treatment Duration Up to 12 months
Dosage 25 mg or 50 mg twice daily, oral solution
Main Assessments Adverse events, vascular health markers, quality of life, drug levels in blood, biomarkers

FAQ

  • What is Etrinabdione and what is it being tested for? Etrinabdione is a new medication being tested for the treatment of Peripheral Arterial Disease (PAD). It's a fully synthetic, new chemical entity that is taken as an oral solution. The study aims to evaluate its safety, tolerability, and potential effectiveness in patients with PAD.
  • Who can participate in this clinical trial? The trial is open to men and women aged 50 to 85 years who have been diagnosed with Peripheral Arterial Disease (PAD) classified as Rutherford Category 2 or 3 (moderate or severe claudication). Participants must also have type 2 diabetes with controlled blood sugar levels (HbA1c < 9%).
  • How long does the trial last and what does it involve? The trial lasts up to 12 months. Participants will take Etrinabdione orally, either 25 mg or 50 mg twice daily. Throughout the study, various tests will be conducted to assess vascular health, clinical improvement, quality of life, and tissue oxygenation. Blood samples will also be taken to measure drug levels and biomarkers.
  • What are the main goals of this clinical trial? The primary goal is to assess the safety and tolerability of Etrinabdione in patients with PAD. Secondary objectives include evaluating its effects on vascularization, clinical improvement, quality of life, tissue oxygenation, hemodynamics, and stenosis. The study will also look at how the drug is processed in the body and its impact on various biomarkers.
  • Are there any specific exclusion criteria for this trial? Yes, there are several exclusion criteria. These include having severe heart conditions, recent surgeries or procedures, certain infections (HIV, hepatitis), planned major amputations, severe hypertension, and blood clotting disorders. Pregnant or breastfeeding women are also excluded, as are those with a history of drug or alcohol abuse.

Ongoing Clinical Trials on Etrinabdione

  • Study on Etrinabdione for Patients with Peripheral Arterial Disease: Evaluating Safety and Tolerability

    Not recruiting

    1 1
    Investigated drugs:
    Spain

Glossary

  • Peripheral Arterial Disease (PAD): A circulatory problem where narrowed arteries reduce blood flow to the limbs, usually the legs. It can cause pain, numbness, and increase the risk of infection.
  • Claudication: Pain or cramping in the legs that occurs during exercise and is relieved by rest. It's a common symptom of PAD.
  • Etrinabdione: A new medication being tested for the treatment of Peripheral Arterial Disease. It's taken as an oral solution.
  • Vascularization: The formation of blood vessels or a network of blood vessels in a part of the body.
  • Hemodynamic: Relating to the flow of blood within the organs and tissues of the body.
  • Stenosis: The abnormal narrowing of a blood vessel or other tubular organ or structure.
  • Ankle/Brachial Index: A test that compares the blood pressure in your ankle with the blood pressure in your arm to determine how well your blood is flowing.
  • Transcutaneous Oximetry (TcPO2): A non-invasive method to measure the oxygen level of tissue under the skin.
  • Biomarkers: Measurable indicators of the severity or presence of some disease state. In this study, they're used to track the effects of the drug and the progression of PAD.
  • Pharmacokinetics: The study of how a drug is processed by the body, including its absorption, distribution, metabolism, and excretion.

References

  1. http://clinicaltrials.eu/trial/study-on-etrinabdione-for-patients-with-peripheral-arterial-disease-evaluating-safety-and-tolerability/